Gene & Cell Therapy and Rare Diseases’ Research
We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.
The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.
Visit LucidCGT ↗ · See the full LucidQuest ecosystem
Our services include (amongst others):
For BioPharma clients:
- Market and competitor insights on R&D, clinical development and commercial activities
- Extensive congress coverage, supporting brand owners with up-to-date intelligence
- Landscape analysis strengthened by expert interviews
- BD&L support
For Investors:
- Due diligence research
- New opportunity identification
- Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews
We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.
Want to better understand and succeed in this complex space? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
November 13, 2026
Obesity Week 2026 Preview: Emerging Therapies and the Obesity Market Landscape
November 13, 2026
Respiratory Strategic Roundup: Clinical Differentiation | Oct 7–Nov 11, 2026
November 12, 2026
Cell and Gene Therapy Strategic Roundup: Safety and Access | Oct 6 – Nov 11, 2026
November 10, 2026
Obesity Strategic Roundup: Emerging Competition | Oct 5 – Nov 6 , 2026
November 5, 2026
ACR 2026 Preview: CAR-T, Emerging Immune Therapies and AI in Rheumatology
November 5, 2026
AHA Scientific Sessions 2026 Preview: Cardiovascular Outcomes, Emerging Therapies and AI
November 5, 2026
Cardiovascular Strategic Roundup: Device Innovation and Treatment Value | Oct 01 – Nov 04, 2026
November 4, 2026
Evestia Clinical Acquires Emtex Life Science | Lucid Diligence Brief
November 4, 2026
Neuroscience Strategic Roundup: Emerging Therapies and Competitive Shifts | Sep 29–Nov 3, 2026
November 3, 2026
SITC 2026 Preview: Emerging Cancer Immunotherapies and Industry Developments
November 3, 2026
Endocrinology Strategic Roundup: Access and Innovation | Sep 29 – Nov 2, 2026
October 30, 2026